13.07.2020 – 20:03
Stephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck
Darmstadt, Germany (ots/PRNewswire)
- Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich
- Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research
- Sibel Health awarded the Nature Spinoff Prize
Merck, a leading science and technology company, today announced the winner of the Future Insight Prize 2020, worth EUR 1 million. This year's topic "Multi-Drug Resistance Breaker" relates to the health category. Prof. Stephan Sieber (44) is being awarded the Future Insight Prize 2020 for his scientific research into fighting multidrug-resistant bacteria. Sieber and his research group at the Technical University of Munich, Germany, are working on ways to overcome antibiotic resistance.
"Only thanks to research and innovative solutions will we be able to win the fight against antimicrobial resistance globally. I cordially congratulate Prof. Stephan Sieber on his work. And it is my wish to see many scientists and companies engage in this vital field of health research," said Jens Spahn, German Federal Minister of Health, in his speech to honor Sieber.
"Antimicrobial resistance poses a major risk for all of humanity. It threatens every medical advance that researchers and developers are pursuing around the globe. That's why we are proud to be able to support Stephan Sieber: a brilliant researcher who has dedicated himself to this highly complex topic. We at Merck have been engaged in the fight against antimicrobial resistance for years, and we launched a new development fund together with other companies just last week," said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
One of Sieber's research projects focuses on PK150, an antibiotic able to stop multi-resistant bacteria in their tracks. His research group has identified two modes of action for PK150: firstly, it interferes with the bacteria's energy metabolism; secondly, it increases the activity of a signal peptidase, which causes the bacteria to burst, thereby destroying them. Sieber, who lectures in Organic Chemistry at the Technical University of Munich, studied and earned his doctorate at Philipps-Universität in Marburg with periods of study abroad including in Boston, USA. He has received numerous awards, including the Klung Wilhelmy Science Award and the Klaus Grohe Prize.
"I would like to accept the Future Insight Prize on behalf of my entire research group," said Sieber. "The award will open up many new opportunities for us." One such aim is to optimize PK150, and the next phase of the research will turn to the clinical development of PK150.
According to current estimates by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 700,000 deaths per year are attributable to antibiotic-resistant bacteria. In its worst-case scenario, the IFPMA anticipates up to 10 million deaths per year by 2050. Merck has joined forces with other pharmaceutical companies in support of the AMR Action Fund. With nearly US$ 1 billion in venture capital at its disposal and under the leadership of the IFPMA, this initiative aims to help biotech companies develop two to four new antibiotics and make them available to patients by the end of the decade.
Merck supports scientists and young researchers
With the Johann Anton Merck Award, presented for the very first time this year, Merck aims to honor outstanding pre-clinical research in the fields of oncology and autoimmunity. Prof. Caroline Dive (58) of the Cancer Research UK Manchester Institute, Manchester, United Kingdom, accepted the EUR 30,000 award.
"Caroline Dive is a globally renowned scientist whose work on circulating tumor cells and liquid biopsies revolutionized the way we diagnose cancer," said Belén Garijo, member of the Executive Board of Merck and CEO Healthcare. "We are very pleased to recognize her as the first Johann Anton Merck Award recipient and look forward to collaborating together to help advance science in oncology."
Prof. Dive and her team of around 100 at the Cancer Research UK Manchester Institute, University of Manchester, United Kingdom, are conducting pre-clinical oncological research into biomarkers to inform cancer patient treatment. One focus of her work is lung cancer and its management using liquid biopsies. Specifically, she studies tumour cells circulating in a patient's blood - a method that could dispense with the need for tissue samples to diagnose cancers and in 2017 she was appointed Commander of the Order of the British Empire for her services to cancer research.
Originally graduating in pharmacy from the University of London, Dive's current research areas include discovery of new drug targets, the selection of drug dose in early clinical trials, investigating mechanisms of drug action and predictive biomarkers to pick the right drug for the right patient.
The Nature Spinoff Prize has been established by Nature Research publishers in partnership with Merck to showcase and celebrate global excellence in the commercialization of academic research through the creation of spinoff companies. Magdalena Skipper, editor-in-chief of Nature, and Stefan Oschmann today presented the award worth EUR 30,000 to Sibel Health, a spinoff of Northwestern University, Illinois, USA.
More information about the winning team, today's other 11 finalists and 32 other promising companies selected by the jury as "ones to watch" can be found here.
The three awards - Future Insight Prize, Johann Anton Merck Award and the Nature Spinoff Prize - were presented today at the Future Insight Virtual Event. All three prizes will be presented again next year at the Curious 2021 - Future Insight Conference.
The Future Insight Prize
The Future Insight Prize puts forth a vision for ambitious dream products in the areas of health, nutrition, and energy. Merck aims to award a research grant of up to EUR 1 million annually to incentivize work that will significantly help to realize this vision by discovering new groundbreaking science or by developing enabling key technologies.
The first Future Insight Prize was awarded in 2019 in the health category for Pandemic Protector to Harvard University and the Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, for the work of Pardis Sabeti, and to Vanderbilt University Medical Center, Nashville, Tennessee, USA, for the work of James Crowe. Merck announced at its 350th anniversary celebrations in 2018 that the prize of up to EUR 1 million would be awarded annually for a period of 35 years. In 2021, the prize will be awarded in the nutrition category for a Food Generator, i.e., for a technology that is able to help feed a growing global population.
Johann Anton Merck
Johann Anton Merck (1756-1805) was the fifth generation to run the Merck pharmacy. He combined hands-on work in the dispensary with scientific research, published in respected journals and demonstrated a curious mind, a passion for innovative concepts and an interest in establishing international networks. It was in this prolific atmosphere that his son, Emanuel Merck (1794-1855), grew up and successfully turned the family's pharmacy into a science-based industrial company.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merck.de/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2019, Merck generated sales of EUR 16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Your contact: firstname.lastname@example.org Phone: +49-6151-72-9591
Original content of: Merck Serono GmbH, transmitted by news aktuell